Showing results (901-910 of 1,007) with videos related to
Sort By:
Pageof 101
Cancers|February 27, 2020
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of ResistanceMohamad Krayem, Philippe Aftimos, Ahmad Najem, et al.Cancers|January 9, 2021
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with PembrolizumabGil Awada, Yanina Jansen, Julia Katharina Schwarze, et al.Cancers|October 17, 2020
Erratum: Krayem, M., et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma. Cancers 2020, 12, 512Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.Nature Communications|January 14, 2021
Age-related and disease locus-specific mechanisms contribute to early remodelling of chromatin structure in Huntington's disease miceRafael Alcalá-Vida, Jonathan Seguin, Caroline Lotz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2018
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan PegolHope S Rugo, Javier Cortes, Ahmad Awada, et al.Blood|March 21, 2024
Paroxysmal nocturnal hemoglobinuria-related thrombosis in the era of novel therapies: a 2043-patient-year analysisCarmelo Gurnari, Hussein Awada, Simona Pagliuca, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancerHarold J Burstein, Yan Sun, Luc Y Dirix, et al.Cancers|July 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512Mohammad Krayem, Philippe Aftimos, Ahmad Najem, et al.Arthritis Care & Research|June 8, 2012
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational studyF Tubach, P Ravaud, E Martin-Mola, et al.Liver Cancer|August 11, 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver CancersJames J Harding, Ahmad Awada, Gael Roth, et al.Pageof 101